Tramway Ventures

Circular Genomics is a biotechnology company based in Albuquerque, New Mexico, focused on developing RNA-based diagnostic and therapeutic assays aimed at treating psychiatric and neurological diseases. Founded in 2021, the company specializes in circular RNA diagnostics, which provide an evidence-based approach to managing depressive disorders. This innovative technology significantly reduces the time required to achieve a therapeutic response in patients, allowing healthcare providers to more effectively diagnose and treat various psychiatric conditions. Through its advancements in RNA diagnostics, Circular Genomics seeks to enhance treatment outcomes for individuals suffering from these challenging illnesses.

Armonica Technologies is an early-stage medtech company specializing in long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin's Glass Armonica, the company has developed a proprietary platform that can sequence a complete human genome in minutes. This innovative technology utilizes nanochannels to guide single nucleic acid molecules through nanopores, allowing for optical readout through Raman spectroscopy. By overcoming the limitations of existing sequencing technologies, Armonica's platform offers life science researchers and clinicians a comprehensive understanding of the genome, including critical insights into all epigenetic modifications. The company holds a portfolio of patented and patent-pending technologies licensed from STC.UNM, positioning it at the forefront of advancements in genomic sequencing.

WaveFront Dynamics is a medical device company focused on developing advanced wavefront diagnostic technology for the vision care industry. Its innovative instruments are designed to assess the visual performance of the human eye by measuring changes dynamically over time, rather than relying on a single snapshot. This capability allows for a comprehensive evaluation of the eye, facilitating enhanced treatment planning for complex visual dysfunction. By leveraging dynamic wavefront measurement, the company aims to improve ophthalmic treatment products and ultimately support eye care professionals in delivering better patient outcomes.

BennuBio, Inc. develops innovative flow cytometry equipment designed for cell sorting and analysis across various applications, including rare cell detection and monitoring. Their flagship product, The Velocyt, enables users to analyze rare events such as activated T cells, immune cells for personalized medicine, fetal cells from maternal blood, and circulating tumor cells. The company also offers spheroid generation systems and high-volume sorting systems, alongside technical support and application services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio aims to improve healthcare outcomes by providing advanced tools for cell counting, sorting, and biomarker detection, accommodating a wide range of sample volumes and particle sizes.

BennuBio, Inc. develops innovative flow cytometry equipment designed for cell sorting and analysis across various applications, including rare cell detection and monitoring. Their flagship product, The Velocyt, enables users to analyze rare events such as activated T cells, immune cells for personalized medicine, fetal cells from maternal blood, and circulating tumor cells. The company also offers spheroid generation systems and high-volume sorting systems, alongside technical support and application services. Founded in 2018 and based in Albuquerque, New Mexico, BennuBio aims to improve healthcare outcomes by providing advanced tools for cell counting, sorting, and biomarker detection, accommodating a wide range of sample volumes and particle sizes.

Armonica Technologies is an early-stage medtech company specializing in long-read DNA sequencing technology aimed at precision medicine applications. Named after Benjamin Franklin's Glass Armonica, the company has developed a proprietary platform that can sequence a complete human genome in minutes. This innovative technology utilizes nanochannels to guide single nucleic acid molecules through nanopores, allowing for optical readout through Raman spectroscopy. By overcoming the limitations of existing sequencing technologies, Armonica's platform offers life science researchers and clinicians a comprehensive understanding of the genome, including critical insights into all epigenetic modifications. The company holds a portfolio of patented and patent-pending technologies licensed from STC.UNM, positioning it at the forefront of advancements in genomic sequencing.